Newsfeeds - Spark Newswire

1 minute read

Opiant Pharmaceuticals Q4 EPS $0.11 Beats $(0.01) Estimate, Sales $13.80M Beat $13.26M Estimate

Today, 7:11 AM

Opiant Pharmaceuticals (NASDAQ:OPNT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.01) by 1200 percent. This is a 168.75 percent increase over losses of $(0.16) per share

OPNT

1 minute read

Earnings

Opiant Pharmaceuticals’s Earnings Outlook

By Benzinga Insights

Today, 7:11 AM

Opiant Pharmaceuticals (NASDAQ:OPNT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that Opiant Pharmaceuticals will report an earnings per share (EPS) of $-0.01.

OPNT

1 minute read

Opiant’s Multi-Dose Nasal Nalmefene Shows Safety, Tolerability In Opioid Overdose

By Vandana Singh

Today, 7:11 AM

Opiant Pharmaceuticals Inc (NASDAQ: OPNT)

OPNT

1 minute read

Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder

By Vandana Singh

Today, 7:11 AM

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has

OPNT

3 minute read

Opiant Pharma Highlights First Patient Dosed In Phase 2 Trial Of OPNT002 For Alcohol Use Disorder

By Benzinga Newsdesk

Today, 7:11 AM

Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking risk levels1 Trial is informed by results from Phase 1 studies that showed

OPNT

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 9, 2021

By Benzinga Insights

Today, 7:11 AM

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.

ABBV

1 minute read

Oppenheimer Initiates Coverage On Opiant Pharmaceuticals with Outperform Rating, Announces Price Target of $42

By Benzinga Newsdesk

Today, 7:11 AM

Oppenheimer analyst Leland Gershell initiates coverage on Opiant Pharmaceuticals (NASDAQ:OPNT) with a Outperform rating and announces Price Target of $42.

OPNT

10 minute read

Earnings Scheduled For November 11, 2021

By Benzinga Insights

Today, 7:11 AM

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.

ACHR

4 minute read

The Daily Biotech Pulse: NRx’s Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill

By Shanthi Rexaline

Today, 7:11 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ACXP

2 minute read

FDA
News

Opiant Reports Received FDA Fast Track Designation For OPNT003 For Treatment Of Opioid Overdose

By Benzinga Newsdesk

Today, 7:11 AM

Fast Track Designation further underscores the potential for OPNT003 to represent a major advance in the treatment of opioid overdose as opioid overdose deaths surge1 This designation enables early and

OPNT